Anocca To Reach Clinical-Stage With T-Cell Therapies After Series B Injection
Swedish Biotech Developing Pipeline Of TCR-T Cellular Therapies
Sweden-based Anocca AB will use a just completed $47m Series B financing to advance its industrialized cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells Scrip.
